| 英文名称 |
中文名称 |
CAS号 |
操作 |
| Research Grade Bamlanivimab (DVV00303) |
BAMLANIVIMAB |
2423943-37-5 |
详细
|
| Oxybutynin chloride |
盐酸奥昔布宁 |
1508-65-2 |
详细
|
| GLP-1 |
胰高血糖素样肽-1（GLP-1） |
87805-34-3 |
详细
|
| Formoterol fumarate dihydrate |
富马酸福莫特罗二水合物 |
183814-30-4 |
详细
|
| Lorlatinib |
劳拉替尼 |
1454846-35-5 |
详细
|
| KIRA6 |
CS-2625 |
1589527-65-0 |
详细
|
| Futibatinib |
FGFR抑制剂(FGFR-IN-1) |
1448169-71-8 |
详细
|
| Pyrotinib dimaleate |
马来酸吡咯替尼 |
1397922-61-0 |
详细
|
| Maleimido-mono-amide-DOTA |
DOTA-马来酰亚胺 |
1006711-90-5 |
详细
|
| PA-8 |
2-amino-5-[3-methoxy-4-(prop-2-en-1-yloxy)phenyl]-3H,4H,5H,6H,7H,8H-pyrido[2,3-d]pyrimidine-4,7-dione |
878437-15-1 |
详细
|
| 6-ethyl-1,2,3,4-tetrahydroanthraquinone |
2-乙基-5,6,7,8-四氢-9,10-蒽醌 |
15547-17-8 |
详细
|
| Rocatinlimab |
诺卡替利单抗 |
2431972-52-8 |
详细
|
| Research Grade Anti-Human CD152 |
|
|
详细
|
| 6-OH-BTA-1 |
6-OH-BTA-1 |
566169-93-5 |
详细
|
| Ponatinib |
帕纳替尼 |
943319-70-8 |
详细
|
| TP003 |
TP-003 |
628690-75-5 |
详细
|
| 2-Fluoro-4-nitrobenzoic acid |
2-氟-4-硝基苯甲酸 |
403-24-7 |
详细
|
| Cabergoline EP Impurity E |
6-Allyldihydronorisolysergic Acid Methyl Ester |
86891-16-9 |
详细
|
| Cabergoline EP Impurity C |
(6aR,9R,10aR)-9-N-[3-(dimethylamino)propyl]-4-N-ethyl-9-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-4,9-dicarboxamide |
126554-50-5 |
详细
|
| 6-Amino-2-(4-dimethylaminophenyl)benzothiazole |
|
909191-20-4 |
详细
|
| Cefepime |
头孢吡肟 |
88040-23-7 |
详细
|
| ABT 263 |
ABT 263 |
923564-51-6 |
详细
|
| Acalabrutinib |
阿卡替尼 |
1420477-60-6 |
详细
|
| Fruquintinib|HMPL-013 |
呋喹替尼 |
1194506-26-7 |
详细
|
| CNV 1014802 hydrochloride |
(2S,5R)-5-(4-((2-氟苄基)氧基)苯基)吡咯烷-2-甲酰胺盐酸盐 |
934240-31-0 |
详细
|
| WT-161 |
CS-2547 |
1206731-57-8 |
详细
|
| MYK-461 |
玛伐凯泰 |
1642288-47-8 |
详细
|
| C188-9 |
432001-19-9 |
432001-19-9 |
详细
|
| DS-3201 |
DS-3201 |
1809336-39-7 |
详细
|
| OUL 35 |
4,4'-Oxybis[benzamide] |
6336-34-1 |
详细
|
| Cabergoline EP Impurity J |
Des-N-allylcabergoline |
153415-36-2 |
详细
|
| Tislelizumab |
替雷利珠单抗 |
1858168-59-8 |
详细
|
| Research Grade Spesolimab |
司柏索利单抗 |
2097104-58-8 |
详细
|
| BMS-986177 |
BMS-986165 |
1802425-99-5 |
详细
|
| (S)-2-((tert-Butoxycarbonyl)amino)-3,3,3-trifluoropropanoic acid |
(S)-2-((叔丁氧基羰基)氨基)-3,3,3-三氟丙酸 |
1932644-89-7 |
详细
|
| MRTX 9768 |
MRTX 9768 |
2629314-68-5 |
详细
|
| FAP-2286 |
FAP2286 |
2581741-18-4 |
详细
|
| IEM1754dihydrobroMide |
IEM 1754 DIHYDROBROMIDE |
162831-31-4 |
详细
|
| NMDA-IN-1 |
2-[[4-[(2-FLUOROPHENYL)METHYL]-1-PIPERIDINYL]METHYL]-1H-BENZIMIDAZOL-6-OL DIHYDROCHLORIDE |
700878-19-9 |
详细
|
| AG-270 |
6-(3-甲氧基苯基)-4-甲基-2-(2-吗啉代乙基)哒嗪-3(2H)-酮盐酸盐 |
13299-99-5 |
详细
|
| Research Grade Anti-Human CD19 |
|
|
详细
|
| GR 89696 fumarate |
GR 89696 FUMARATE |
126766-32-3 |
详细
|
| Chidamide |
西达本胺 |
743420-02-2 |
详细
|
| N-Desalkylflurazepam |
7-氯-5-(2-氟苯基)-1,3-二氢-2H-1,4-苯并二氮杂卓-2-酮 |
2886-65-9 |
详细
|
| Cabergoline EP Impurity B |
卡麦角林 EP杂质 B |
166533-36-4 |
详细
|
| Remibrutinib |
LOU-064 |
1787294-07-8 |
详细
|
| Cabergoline EP Impurity G |
(8β)-N-[3-(Methylamino)propyl]-6-(2-propenyl)-ergoline-8-carboxamide |
478815-26-8 |
详细
|
| Ondansetron hydrochloride |
盐酸昂丹司琼 |
103639-04-9 |
详细
|
| TOFA |
5-(十四烷基氧)-2-糠酸 |
54857-86-2 |
详细
|
| Research Grade Sotatercept (DHC33102) |
|
1001080-50-7 |
详细
|
| 5-Carboxamidotryptamine maleate |
5-carboxyamidotryptamine maleate |
74885-72-6 |
详细
|
| PI 828 |
8-(4-氨基苯基)-2-(4-吗啉基)-4H-1-苯并吡喃-4-酮 |
942289-87-4 |
详细
|
| Ponatinib Mono-hydrochloride |
泊那替尼盐酸盐 |
1114544-31-8 |
详细
|
| GSK 343 |
GSK343 |
1346704-33-3 |
详细
|
| Brexpiprazole |
依匹哌唑 |
913611-97-9 |
详细
|
| Melatonine |
褪黑素 |
73-31-4 |
详细
|
| Pemigatinib |
培米加替尼 |
1513857-77-6 |
详细
|
| Atomoxetine HCL |
盐酸托莫西汀 |
82248-59-7 |
详细
|
| ITKinhibitor2 |
ITK inhibitor 2 |
1309784-09-5 |
详细
|
| (R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3,3,3-trifluoropropanoicacid |
(R)-2-((9H-芴-9-基)甲氧基)羰基)氨基)-3,3,3-三氟丙酸 |
1704706-86-4 |
详细
|
| Silybin A |
水飞蓟宾 |
22888-70-6 |
详细
|
| Cabergoline EP Impurity A |
6-(2-丙烯基)二氢麦角酸 |
"81409-74-7 |
详细
|
| (R)-2-((tert-butoxycarbonyl)amino)-3,3,3-trifluoropropanoic acid |
(R)-2-(TERT-BUTOXYCARBONYLAMINO)-3,3,3-TRIFLUOROPROPANOIC ACID |
1354225-89-0 |
详细
|
| 5-Aza-2'-deoxycytidine |
地西他滨 |
2353-33-5 |
详细
|
| Remimazolam Tosilate |
甲苯磺酸瑞马唑仑 |
1425904-79-5 |
详细
|
| Capmatinib 2HCl |
卡马替尼盐酸盐 |
1197376-85-4 |
详细
|
| Glumetinib |
谷美替尼 |
1642581-63-2 |
详细
|
| MRTX-1257 |
MRTX-1257 |
2206736-04-9 |
详细
|
| Sotorasib |
AMG510 单一构型 |
2296729-00-3 |
详细
|
| 2-Ethyl Anthraquinone |
2-乙基蒽醌 |
84-51-5 |
详细
|
| Sabatolimab |
SABATOLIMAB |
2252262-24-9 |
详细
|
| orellanine |
orellanine |
37338-80-0 |
详细
|
| Cabergoline EP Impurity D |
卡麦角林杂质D(EP) |
85329-86-8 |
详细
|
| Tepotinib |
特泊替尼 |
1100598-32-0 |
详细
|
| Dabrafenib Mesylate |
达帕菲尼甲磺酸盐 |
1195768-06-9 |
详细
|
| Belzutifan |
PT2977 |
1672668-24-4 |
详细
|
| Mirikizumab |
Mirikizumab |
1884201-71-1 |
详细
|
| Magrolimab |
MAGROLIMAB (莫洛利单抗 ) |
2169232-81-7 |
详细
|
| 6-OH-BTA-0 |
6-OH-BTA-0 |
178804-18-7 |
详细
|
| PD 180970 |
PD180970 |
287204-45-9 |
详细
|
| Baricitinib |
巴瑞克替尼 |
1187594-09-7 |
详细
|
| Glasdegib |
格拉斯吉布 |
1095173-27-5 |
详细
|
| Gilteritinib |
吉列替尼 |
1254053-43-4 |
详细
|
| TPX-0005 |
洛普替尼 |
1802220-02-5 |
详细
|
| Ravulizumab |
Immunoglobulin G2/G4, anti-(human complement C5) (human-Mus musculus ALXN1210 heavy chain), disulfide with human-Mus musculus ALXN1210 κ-chain, dimer |
1803171-55-2 |
详细
|
| Xanthene |
氧杂蒽 |
92-83-1 |
详细
|
| Ethyl3-oxo-3-(4-nitrophenyl)propanoate |
对硝基苯甲酰醋酸乙酯 |
838-57-3 |
详细
|
| Apremilast Impurity 1 |
Apremilast Impurity 57 |
2487573-01-1 |
详细
|
| Lonodelestat |
LONODELESTAT |
906547-89-5 |
详细
|
| MRTX0902 |
MRTX0902 |
2654743-22-1 |
详细
|
| intermediate |
N-(2-(6--羟基-1,2,3,4-四氢萘-2-基)-5-(甲氧基苯基)乙酰胺 |
722520-42-5 |
详细
|
| Research Grade Acazicolcept |
单抗 |
2270247-50-0 |
详细
|
| Cabergoline EP Impurity F |
Ergoline-8-carboxylic acid, 6-(2-propenyl)-, (8-alpha)- |
86891-15-8 |
详细
|
| Capmatinib |
卡马替尼 |
1029712-80-8 |
详细
|
| Trametinib DMSO solvate |
曲美替尼二甲亚砜 |
1187431-43-1 |
详细
|
| Reltecimod |
Reltecimod |
1447799-33-8 |
详细
|
| IQ3 |
IQ 3 |
312538-03-7 |
详细
|
| Leniolisibphosphate |
化合物 T5166L |
1354691-97-6 |
详细
|
| Adagrasib |
MRTX-849 |
2326521-71-3 |
详细
|
| camlipixant |
BLU-5937 |
1621164-74-6 |
详细
|